The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Strategy Stock: Buy, Sell, or Hold? Until Bitcoin's price begins to move significantly higher, it will be hard to trust Strategy.
Prediction: This Will Be the Next $5 Trillion Company Alphabet isn't that far away from becoming a $5 trillion company.
Can Brookfield Corporation Stock Double From Here? Here's What Its Plan Value Says. Brookfield isn't trying to win the next quarter, but building a valuable business over the years, if not decades.
The 4% Rule Isn't Actually a Rule, Says Its Creator There are plenty of misconceptions surrounding the 4% rule, which applies to withdrawals from retirement savings.
Iran War Fallout: Kuwait Hires 3 Pentagon Contractors to Build It a $2.5 Billion Defense System Citing emergency conditions in the context of the Iraq war, the State Department supports selling advanced defense tech to Kuwait.
MGK vs. QQQ: Which Tech-Stock ETF Is a Better Buy? If you want to own America's major tech names, it's tough to beat the Invesco QQQ Trust.
How Much Will SpaceX Stock Be Worth by 2030? Here's What History Says. SpaceX is reportedly seeking a valuation of up to $2 trillion for its initial public offering.
Why IonQ Stock Surged This Week Quantum computing stocks have been hot recently.
Why Quantum Computing Stock Skyrocketed This Week Quantum Computing's first-quarter report delivered the good news investors were hoping for.
3 Dividend Stocks Warren Buffett Would Buy in a Market Crash Get greedy for these blue chip dividend stocks when Wall Street gets fearful.
Warren Buffett Successor Greg Abel Just More Than Tripled Berkshire's Stake in This "Magnificent Seven" Stock. Is It a Buy? The new Berkshire Hathaway CEO is putting serious money behind a tech giant that just posted its fastest revenue growth in more than two years.
Nvidia vs. Cerebras: Better AI Stock to Buy Now Cerebras aims to take on leader Nvidia in the AI chip market.
I'd Buy This Growth Stock After Its 35% Plunge Dutch Bros looks like a buy with the stock well off its highs.
BlackRock’s CORO ETF Beat Its Benchmark by 6 Points. One Firm Just Bought $55 Million This ETF delivers dynamic exposure to international equities through an active country rotation strategy targeting global market trends.
Want to Retire Abroad? Here Are the Top 3 Spots for Americans. If you've ever dreamed of making a life in a foreign country, here's where you're likely to meet other Americans.
What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings Thermon Group delivers industrial heating solutions worldwide, serving sectors from energy and transit to tech and manufacturing.
KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet This engineering and technology firm delivers mission-critical solutions to government and industrial clients worldwide.
Is Micron the Next Nvidia? Micron is having an Nvidia moment. That doesn't make it the next Nvidia.
ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown ServisFirst Bancshares delivers commercial and retail banking services across the Southeast with a relationship-driven approach.
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
What Is the Cheapest "Magnificent Seven" Stock? There are two companies investors should consider for bargain values.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Nvidia Stock Is Poised to Rocket From the Booming Space Economy Nvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
With YMM Down 29%, First Beijing Bought 13 Million More Shares Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
GDS Was Already Up 47% — Pinpoint Tripled Its Stake Anyway GDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
Why Plug Power Stock Skyrocketed This Week Plug Power served up some promising news for investors this week.
Snapchat: Don't Rush to Buy This Social Media Stock Snap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
M&G Shaved 2.4% of Methanex After a Near-Doubling Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Where Could Palantir Be in 10 Years? The Bull and Bear Cases. Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
Why Poet Technologies Stock Skyrocketed This Week Poet's new contract announcement powered huge gains for the stock.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Why Would Anyone Buy SPYM Instead of QQQ? Buying the S&P 500 instead of the Qs could help you avoid relying too heavily on tech stocks.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Why Everyone Is Talking About Lumentum Stock -- and Why Investors Should Care Everyone knows AI needs powerful chips. But what if the next big AI opportunity is actually the technology helping all of those systems communicate with each other?
Oklo's Biggest Opportunity Might Also Be Its Biggest Problem Oklo's nuclear story is getting stronger, but the stock's valuation already prices in a lot of success. Here's what investors need to know.
This 7.2% Yield Is Safe and On Stronger Ground Than It Seems Consumer staples makers are dealing with material headwinds, but this one's huge yield looks sustainable.
Alibaba Stock May Be One of the Safest Ways to Play the AI Boom Right Now AI investing often comes with high expectations and high volatility. Alibaba stock offers a different opportunity altogether.
Navitas vs. Poet: Which AI Infrastructure Stock Is the Better Buy? Two AI infrastructure stocks are surging, but only one has stronger validation. Here's what investors should know before chasing the next move.
Citigroup's Quiet Turnaround: Is the Stock Finally Worth Buying? Shares of Citigroup have risen by more than 60% over the past year, trouncing the performance of many peers.
A Merit Medical Systems Director Sold 5,000 Company Shares. What Does That Mean for Investors? This medical device innovator, serving hospitals worldwide, reported a notable insider sale amid a year of share price declines.
Is Amazon About to Join the $3 Trillion Club? After hitting an all-time high earlier this month, the online leader is closing in on a juicy milestone.
My Top Artificial Intelligence Stock for Retirees (Hint: It's Not Nvidia) Unlike Nvidia, Cisco offers AI growth with lower volatility and a more predictable income.
Is the iShares EEMA ETF a Buy After Gateway Wealth Partners Raised Its Stake by $17.5 Million? The iShares MSCI Emerging Markets Asia ETF tracks a diverse mix of Asian equities, offering exposure to regional growth and sector trends.
3 Chip Designers That Could Make Investors a Fortune All three companies are growing their chip business at a rapid pace.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains.
Is Opendoor Stock a Buy After Its CEO Purchased 100,000 Shares? This digital real estate platform, focused on home transactions, reported a recent insider buy amid notable one-year price gains.
